In a report released today, Ritu Baral from TD Cowen maintained a Hold rating on Spero Therapeutics (SPRO – Research Report). The company’s shares opened today at $1.16.
According to TipRanks, Baral is a 5-star analyst with an average return of 12.8% and a 46.67% success rate. Baral covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Madrigal Pharmaceuticals, and SAGE Therapeutics.
Spero Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See today’s best-performing stocks on TipRanks >>
SPRO market cap is currently $61.48M and has a P/E ratio of 120.83.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SPRO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics (SPRO) Company Description:
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Read More on SPRO:
- Spero Therapeutics reports Q3 EPS (6c), consensus (3c)
- Is SPRO a Buy, Before Earnings?
- Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
- Spero Therapeutics appoints Rajavelu as CFO, CBO
- Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
